English  |  正體中文  |  简体中文  |  0  
???header.visitor??? :  53284193    ???header.onlineuser??? :  710
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"shao y y"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 116-140 of 396  (16 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-08-31T06:42:23Z Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy Shao Y.-Y.; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:42:20Z Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma Liao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; ANN-LII CHENG; Yang J.C.-H.; Lai M.-S.
臺大學術典藏 2021-08-31T06:42:19Z Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; Lu L.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:49Z Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:49Z Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏 2021-08-31T06:29:49Z High serum transforming growth factor-�]1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib Lin T.-H.; Shao Y.-Y.; Chan S.-Y.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:49Z The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; ANN-LII CHENG; Yang J.C.H.; Lai M.-S.
臺大學術典藏 2021-08-31T06:29:47Z Young patients with colorectal cancer have increased risk of second primary cancers Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; ANN-LII CHENG; Yeh K.-H.; Lai M.-S.
臺大學術典藏 2021-08-31T06:29:45Z Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice Liang Y.-H.; Shao Y.-Y.; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏 2021-08-31T06:29:43Z Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma Shao Y.-Y.; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:43Z Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏 2021-08-31T06:29:43Z Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG; Ou D.-L.
臺大學術典藏 2021-08-31T06:29:42Z Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma Lin H.-H.; Feng W.-C.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:40Z Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; ANN-LII CHENG; Lai M.-S.; Yeh K.-H.
臺大學術典藏 2021-08-31T06:29:39Z Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer Liang Y.-H.; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏 2021-08-31T06:29:38Z Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A.
臺大學術典藏 2021-08-31T06:29:37Z Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study Lu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:35Z National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients Shao Y.-Y.; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:34Z High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma Shao Y.-Y.; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏 2021-08-31T06:29:34Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C.
臺大學術典藏 2021-08-31T06:29:33Z Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells Shao Y.-Y.; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:26Z A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma Yang S.-H.; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏 2021-08-31T06:29:24Z Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏 2021-08-31T06:29:23Z Considerations of heterogeneity in clinical trials for hepatocellular carcinoma Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:22Z Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma Shao Y.-Y.; Li Y.-S.; Hsu H.-W.; Lin H.; Wang H.-Y.; Wo R.R.; ANN-LII CHENG; Hsu C.-H.

Showing items 116-140 of 396  (16 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page